

## Suven secures product patents in Israel, Japan, NZ, SL

16 April 2019 | News | By Manbeena Chawla

**The granted claims of the patents include the class of selective 5-HT4 and M1 PAM compounds**



Suven Life Sciences Ltd (Suven) has announced that the grant of one (1) product patent from Israel (257869), one (1) product patent from Japan (6466602), one (1) product patent from New Zealand (737892) and one (1) product patent from Sri Lanka (16614) corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2036 and 2029 respectively.

The granted claims of the patents include the class of selective 5-HT4 and M1 PAM compounds and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Pain, Parkinson Disease and Schizophrenia etc.

"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally" says Venkat Jasti, CEO of Suven.